789pprognostic Factors for Survival and Sequencing of Life-extending Therapies in Metastatic Castration Resistant Prostate Cancer (mcrpc) Patients (pts) in Post-docetaxel (d) Setting.

S. Oudard1, A. Angelergues1, I. Gonzalez Maeso2, N. Delanoy1, A. Flechon3, M. Özgüroğlu4, D.E. Castellano5, A. Guillot6, S. Le Moulec7, E. Esteban8, J. Munarriz9, B. Campos10, J. Bellmunt11 Medical Oncology Service, Georges Pompidou Hospital and Rene Descartes University, Paris, FRANCE Medical Oncology Department, University Hospital del Mar-IMIM, Barcelona, SPAIN Oncology Departement, Centre Léon Bérard, Lyon, FRANCE Department of Medical Oncology, Istanbul University Cerrahpasa, Istanbul, TURKEY Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, SPAIN Medical Oncology, Institut de Cancérologie de la Loire, Saint Priest en Jarez, FRANCE Oncologie Medicale, Hopital du Val de Grace Val de Grace, Paris, FRANCE Oncology Department, Hospital Universitario Central de Asturias, Oviedo, SPAIN Oncology Department, Hospital Provincial de Castellon, Castellon, SPAIN Oncoloxia Médica, Hospital Universitario Lucus Augusti de Lugo, Hospital Universitario Lucus Augusti (Lugo), SPAIN Oncology Department, University Hospital del Mar, Barcelona, SPAIN